Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 9Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 2Carcinoma, Neuroendocrine 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Lung Neoplasms 1Intracranial Germ Cell CNS Tumor, Childhood 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

Etoposide 10Cisplatin 7Carboplatin 6tislelizumab 2camrelizumab 2atezolizumab 2anlotinib 2Topotecan 2Irinotecan 2Drug Therapy 2Bevacizumab 2temsirolimus 1spartalizumab 1oblimersen 1obinutuzumab 1lutetium Lu 177 dotatate 1gossypol acetic acid 1durvalumab 1ceralasertib 1apatinib 1Temozolomide 1Sirolimus 1Podophyllotoxin 1Platinum 1Paclitaxel 1NVP-BKM120 1Injections 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × EC regimen × Clear all
NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Shanghai Henlius Biotech

Phase 3 Active not recruiting
200 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡